An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa - Full Text View

Sponsored by:	Allergan
Information provided by:	Allergan
ClinicalTrials.gov Identifier:	NCT00661479

Purpose

This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.

Condition	Intervention	Phase
Retinitis Pigmentosa	Drug: Brimonidine Tartrate	Phase I Phase II

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Single Blind (Subject), Single Group Assignment, Safety/Efficacy Study

Resource links provided by NLM:

Genetics Home Reference related topics: Lenz microphthalmia syndrome oculofaciocardiodental syndrome Peters plus syndrome X-linked juvenile retinoschisis

Drug Information available for: Brimonidine Brimonidine tartrate

U.S. FDA Resources

Further study details as provided by Allergan:

Primary Outcome Measures:

Change in Visual Acuity [ Time Frame: Month 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Contrast sensitivity [ Time Frame: Day 1 - Month 12 ] [ Designated as safety issue: No ]
Patient questionnaires [ Time Frame: Day 1 - Month 12 ] [ Designated as safety issue: No ]

Estimated Enrollment:	25
Study Start Date:	July 2008
Estimated Study Completion Date:	July 2010
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Group A: 100 µg Brimonidine implant in study eye and sham in fellow eye	Drug: Brimonidine Tartrate Group A: 100 µg Brimonidine Tartrate in study eye and sham in fellow eye using Posterior Segment Drug Delivery System (PS DDS) Applicator on Day 1
2: Experimental Group B: 100 µg Brimonidine implant in study eye and sham in fellow eye	Drug: Brimonidine Tartrate Group B: 100 µg Brimonidine Tartrate in study eye and sham in fellow eye Posterior Segment Drug Delivery System (PS DDS) Applicator on Day 1
3: Experimental Group B: 200 µg Brimonidine implant in study eye and sham in fellow eye	Drug: Brimonidine Tartrate Group B: 200 µg Brimonidine Tartrate in study eye and sham in fellow eye using Posterior Segment Drug Delivery System (PS DDS) Applicator on Day 1
4: Experimental Group B: 400 µg Brimonidine implant in study eye and sham in fellow eye	Drug: Brimonidine Tartrate Group B: 400 µg Brimonidine Tartrate in study eye and sham in fellow eye using Posterior Segment Drug Delivery System (PS DDS) Applicator on Day 1

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Retinitis Pigmentosa in both eyes
Visual acuity between 20/40 to count fingers

Exclusion Criteria:

Growth of new blood vessels in the eye
Any intraocular surgery or laser in either eye in the last 6 months prior to Screening visit or between the Screening visit and Day 1
Any ocular disease that can interfere with diagnosis and or assessment of disease progression
Significant near-sightedness
HIV
Female patients who are pregnant, nursing, or planning pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00661479

Contacts

Contact: Allergan Inc.

clinicaltrials@allergan.com

Locations

United States, Texas
	Recruiting
Arlington, Texas, United States
France
	Recruiting
Paris, France
Germany
	Recruiting
Tubingen, Germany
Portugal
	Recruiting
Coimbra, Portugal

Sponsors and Collaborators

Allergan

Investigators

Study Director:

Medical Director

Allergan

More Information

No publications provided

Responsible Party:	Allergan, Inc. ( Therapeutic Area Head )
Study ID Numbers:	190342-028D
Study First Received:	October 29, 2007
Last Updated:	March 9, 2009
ClinicalTrials.gov Identifier:	NCT00661479 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Neurotransmitter Agents
Adrenergic alpha-Agonists
Adrenergic Agents
Eye Diseases
Retinitis
Retinal Degeneration
Cardiovascular Agents
Antihypertensive Agents

Adrenergic Agonists
Cone Rod Dystrophy
Pigmentary Retinopathy
Genetic Diseases, Inborn
Retinitis Pigmentosa
Eye Diseases, Hereditary
Retinal Diseases
Brimonidine

Additional relevant MeSH terms:

Neurotransmitter Agents
Adrenergic alpha-Agonists
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Eye Diseases
Physiological Effects of Drugs
Retinitis
Retinal Degeneration
Cardiovascular Agents

Antihypertensive Agents
Pharmacologic Actions
Adrenergic Agonists
Genetic Diseases, Inborn
Therapeutic Uses
Retinitis Pigmentosa
Eye Diseases, Hereditary
Retinal Diseases
Brimonidine

ClinicalTrials.gov processed this record on July 02, 2009